<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585933</url>
  </required_header>
  <id_info>
    <org_study_id>1014</org_study_id>
    <secondary_id>09.3.3-LMT-K-712</secondary_id>
    <nct_id>NCT03585933</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Myocardial Fibrosis in Severe Aortic Valve Stenosis</brief_title>
  <acronym>FIB-AS</acronym>
  <official_title>Prognostic Value of Myocardial Fibrosis in Severe Aortic Valve Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vilnius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vilnius University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Degenerative aortic valve stenosis (AS) is the most common valve heart disease in the&#xD;
      developed Western countries. The hemodynamic progression of AS occurs over time and leads to&#xD;
      LV hypertrophy (LVH) as a compensation mechanism of the heart. Morphological changes such as&#xD;
      increasing muscle fibre thickness, collagen volume, and interstitial fibrosis occur in AS&#xD;
      patients. These changes result in left ventricular (LV) diastolic and systolic dysfunction&#xD;
      and, consequently, to with AS related symptoms. When symptoms associated with AS appear,&#xD;
      patients' prognosis is poor if surgical aortic valve replacement (SAVR) or a trans-catheter&#xD;
      aortic valve implantation (TAVI) is not performed.&#xD;
&#xD;
      Primary hypothesis of the research: fibrotic changes in the myocardium are related to&#xD;
      immediate (in hospital) or long-term complications (MACE and all-cause mortality) in patients&#xD;
      with severe AS.&#xD;
&#xD;
      The goal of the study is to determine the prognostic implications of focal as well as diffuse&#xD;
      myocardial fibrosis in patients with severe aortic valve stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AS is the most common valvular heart condition in the Western world. In response to increased&#xD;
      afterload imposed by AS adaptive left ventricular (LV) remodelling occurs which in a course&#xD;
      of a disease transitions from LV hypertrophy to maladaptive changes in the myocardium leading&#xD;
      to cardiac decompensation and symptoms development. This transition is predominantly driven&#xD;
      by myocardial fibrosis and myocyte cell death. Increasing evidence have demonstrated that&#xD;
      presence of myocardial fibrosis, detected by cardiovascular magnetic resonance (CMR), could&#xD;
      serve as an early marker of LV decompensation and predict adverse outcomes in patients with&#xD;
      aortic stenosis. Currently, the indications for valvular replacement are based on the&#xD;
      stenosis severity evaluated by echocardiography and the presence of symptoms.&#xD;
&#xD;
      The objective of the project is to identify parameters of non-invasive imaging modalities&#xD;
      (two-dimensional echocardiography with an extended myocardial deformation analysis, 1.5 T CMR&#xD;
      with T1 parametric map and late gadolinium enhancement (LGE) predictive of cardiac&#xD;
      decompensation and to evaluate the prognostic significance of myocardial fibrotic changes in&#xD;
      patients with severe degenerative AS. In patients with suspicion of cardiac amyloidosis,&#xD;
      99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy will be performed.&#xD;
&#xD;
      Study design: a prospective, open, case-driven, multicentre study (Lithuania, Denmark).&#xD;
&#xD;
      Investigators will assess LV structural and functional alterations before and 12 months after&#xD;
      aortic valve intervention. Cardiac imaging data will be aligned with histopathological data&#xD;
      from myocardial tissue samples collected at the time of aortic valve replacement in SAVR&#xD;
      group. In patients with suspicion of cardiac amyloidosis, DPD scintigraphy and further&#xD;
      evaluation regarding amyloidosis will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of all-cause mortality and MACE (Acute myocardial infarction, stroke, heart failure requiring hospitalisation)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short term mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Intrahospital or 30 days mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lengh of hospital stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the event ( deathe of MACE)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Aortic Stenosis, Calcific</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac magnetic resonance imaging</intervention_name>
    <description>Echocardiography: assessment of aortic stenosis severity, evaluation of LV diastolic and systolic function; CMR: chambers quantification, LGE, T1 mapping; Intraoperative myocardial tissue biopsy for patients undergoing SAVR; DPD scintigraphy: assessment of cardiac transthyretin amyloidosis</description>
    <other_name>echocardiography</other_name>
    <other_name>Intra-operative myocardial biopsy</other_name>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, myocardial tissue samples obtained intra-operatively&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe aortic stenosis without significant coronary artery disease (CAD),&#xD;
        eligible for aortic valve intervention (SAVR or TAVI).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe aortic stenosis (aortic valve area &lt;1.0cm2 or aortic valve area index &lt;0.6&#xD;
             cm2/m2&#xD;
&#xD;
          -  Age â‰¥18 years.&#xD;
&#xD;
          -  Signed informed patient consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe valvular disease other than AS.&#xD;
&#xD;
          -  Significant coronary heart disease requiring revascularisation.&#xD;
&#xD;
          -  History of myocardial infarction.&#xD;
&#xD;
          -  Previous cardiac surgery.&#xD;
&#xD;
          -  Severe renal impairment eGFR &lt;30ml/min/1.73m2.&#xD;
&#xD;
          -  Any absolute contraindication to CMR.&#xD;
&#xD;
          -  Inherited or acquired cardiomyopathy.&#xD;
&#xD;
          -  Other medical conditions that limits life expectancy or precludes SAVR or TAVI.&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Mental condition rendering the patient unable to understand the nature, scope and&#xD;
             possible consequences of the study or to follow the protocol&#xD;
&#xD;
          -  Patients in permanent atrial fibrillation.&#xD;
&#xD;
          -  Significant chronic obstructive pulmonary disease (FEV1 &lt;70% of predicted value)&#xD;
&#xD;
          -  Patient with implanted devices (pacemaker, ICD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Sogaard, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros clinics</name>
      <address>
        <city>Vilnius</city>
        <zip>08416</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vilnius University</investigator_affiliation>
    <investigator_full_name>Peter Sogaard,MD DMSc</investigator_full_name>
    <investigator_title>Peter Sogaard, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Myocardial fibrosis</keyword>
  <keyword>Severe aortic stenosis</keyword>
  <keyword>Cardiovascular magnetic resonance</keyword>
  <keyword>Scintigraphy</keyword>
  <keyword>SAVR/TAVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

